Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Italfarmaco |
---|---|
Information provided by: | Italfarmaco |
ClinicalTrials.gov Identifier: | NCT00570661 |
The present study has been designed in order to evaluate safety and tolerability of ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and methotrexate, with or without previously used biologic agents, and to have a preliminary evaluation of efficacy of ITF2357 in the treatment of SOJIA.
ITF2357 will be administered orally at the daily cumulative dose of 1.5 mg/kg: this dose in children/young adults is considered roughly equivalent to the dose of 1 mg/kg/day in adults, which so far has been proven to be free of any relevant safety concerns both in healthy volunteers and in patients.
Condition | Intervention | Phase |
---|---|---|
Active Systemic Onset Juvenile Idiopathic Arthritis |
Drug: ITF2357 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA) |
Estimated Enrollment: | 18 |
Study Start Date: | August 2006 |
Study Completion Date: | June 2008 |
Ages Eligible for Study: | 2 Years to 25 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Active disease for at least one month prior to enrolment as defined by the following criteria:
Presence of arthritis plus at least one of the following:
Previous treatment with biologics, if any, during at least three months without satisfactory effect or with drug intolerability, discontinued for at least the period specified below before patient's enrolment:
Exclusion Criteria:
Responsible Party: | Italfarmaco ( Tiziano Oldoni ) |
Study ID Numbers: | DSC/05/2357/19, DSC/05/2357/19 2006-000089-35 |
Study First Received: | December 10, 2007 |
Last Updated: | November 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00570661 |
Health Authority: | Italy: Ministry of Health; Serbia: medicines and medical device agency of Serbia; Romania: ministry of public health national medicines agency |
Autoimmune Diseases Arthritis, Juvenile Rheumatoid Musculoskeletal Diseases Joint Diseases |
Arthritis Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases |
Immune System Diseases |